Model development for determining the efficacy of a combination coating for the prevention of perioperative device related infections: A pilot study

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 101, Issue 7, 2013, Pages 1143-1153

  Sinclair, Kristofer D ^a,b   Pham, Theresa X ^b   Williams, Dustin L ^a,b,c   Farnsworth, Ryan W ^b   Loc Carrillo, Catherine M ^a,b   Bloebaum, Roy D ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c University of Utah   (United States)

Author keywords

animal model; antimicrobial; controlled drug release; titanium; total joint replacement

Indexed keywords

ANIMAL MODEL; ANTIMICROBIAL; BACTERIAL INFECTIONS; COMBINATION COATINGS; CONTROLLED DRUG RELEASE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RESISTANT STRAINS; TOTAL JOINT REPLACEMENT;

ARTHROPLASTY; BACTERIA; ENZYME INHIBITION; TITANIUM;

COATINGS;

ANTIBIOTIC AGENT; CATIONIC STEROIDAL ANTIMICROBIAL 13; TITANIUM; UNCLASSIFIED DRUG;

AGGLUTINATION TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BONE GROWTH; BONE IMPLANT; BONE REMODELING; BONE TISSUE; COLONY FORMING UNIT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEVICE INFECTION; DRUG EFFICACY; FEMALE; FEMUR CONDYLE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFECTION PREVENTION; JOINT PROSTHESIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PERIOPERATIVE PERIOD; PILOT STUDY; SHEEP;

ANIMAL MODEL; ANTIMICROBIAL; CONTROLLED DRUG RELEASE; TITANIUM; TOTAL JOINT REPLACEMENT;

ANIMALS; ANTI-INFECTIVE AGENTS; COATED MATERIALS, BIOCOMPATIBLE; MATERIALS TESTING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PILOT PROJECTS; PROSTHESES AND IMPLANTS; SHEEP; STAPHYLOCOCCAL INFECTIONS; STEROIDS; TITANIUM;

EID: 84884202180     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32924     Document Type: Article

References (36)

1. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A,. National hospital discharge survey: 2007 summary. Natl Health Stat Report 2010: 1-20, 24.
2. Walid MS, Robinson JS, 3rd, Robinson ER, Brannick BB, Ajjan M, Robinson JS Jr,. Comparison of outpatient and inpatient spine surgery patients with regards to obesity, comorbidities and readmission for infection. J Clin Neurosci 2010; 17: 1497-1498.
3. Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M,. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg American Volume 2005; 87: 1487-1497.
4. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr BM,. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-386.
5. Klein E, Smith DL, Laxminarayan R,. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007; 13: 1840-186.
6. Lowy FD,. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003; 111: 1265-1273.
7. Chambers HF,. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7: 178-182.
8. Dantas G, Sommer MO, Oluwasegun RD, Church GM,. Bacteria subsisting on antibiotics. Science 2008; 320: 100-103.
9. Gristina AG,. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 1987; 237: 1588-1595.
10. Costerton JW, Stewart PS, Greenberg EP,. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-1322.
11. Costerton JW,. The Biofilm Primer: Genetic Efficiency of Biofilms. Heidelberg: Springer; 2007. pp 74-75.
12. Antoci V, Jr., Adams CS, Parvizi J, Ducheyne P, Shapiro IM, Hickok NJ,. Covalently attached vancomycin provides a nanoscale antibacterial surface. Clin Orthop Relat Res 2007; 461: 81-87.
13. Darouiche RO, Mansouri MD, Zakarevicz D, Alsharif A, Landon GC,. In vivo efficacy of antimicrobial-coated devices. J Bone Joint Surg Am 2007; 89: 792-797.
14. Gollwitzer H, Ibrahim K, Meyer H, Mittelmeier W, Busch R, Stemberger A,. Antibacterial poly(D,L-lactic acid) coating of medical implants using a biodegradable drug delivery technology. J Antimicrob Chemother 2003; 51: 585-591.
15. Vester H, Wildemann B, Schmidmaier G, Stockle U, Lucke M,. Gentamycin delivered from a PDLLA coating of metallic implants: in vivo and in vitro characterisation for local prophylaxis of implant-related osteomyelitis. Injury 2010; 41: 1053-1059.
16. Jacqueline C, Amador G, Caillon J, Le Mabecque V, Batard E, Miegeville AF, Biek D, Ge Y, Potel G, Hamel A,. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010; 65: 1749-1752.
17. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ,. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother 2008; 61: 365-370.
18. Isogai E, Isogai H, Takahashi K, Okumura K, Savage PB,. Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria. Oral Microbiol Immunol 2009; 24: 170-172.
19. Epand RF, Pollard JE, Wright JO, Savage PB, Epand RM,. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother 2010; 54: 3708-3713.
20. Lai XZ, Feng Y, Pollard J, Chin JN, Rybak MJ, Bucki R, Epand RF, Epand RM, Savage PB,. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res 2008; 41: 1233-1240.
21. Bucki R, Sostarecz AG, Byfield FJ, Savage PB, Janmey PA,. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother 2007; 60: 535-545.
22. Sinclair KD, Pham TX, Farnsworth RW, Williams DL, Loc-Carrillo C, Horne LA, Ingebretsen SH, Bloebaum RD,. Development of a broad spectrum polymer released antimicrobial coating for the prevention of resistant strain bacterial infections. J Biomed Mater Res A 2012; 100A: 2732-2738.
23. Bloebaum RD, Willie B.M., Mitchell BS, Hofmann AA,. Relationship between bone ingrowth, mineral apposition rate, and osteoblast activity. J Biomed Mater Res A 2007; 81A: 505-514.
24. Hofmann AA, Bloebaum RD, Bachus KN,. Progression of human bone ingrowth into porous-coated implants. Rate of bone ingrowth in humans. Acta Orthop Scand 1997; 68: 161-166.
25. Willie BM, Bloebaum RD, Bireley WR, Bachus KN, Hofmann AA,. Determining relevance of a weight-bearing ovine model for bone ingrowth assessment. J Biomed Mater Res A 2004; 69: 567-576.
26. Li C, Lewis MR, Gilbert AB, Noel MD, Scoville DH, Allman GW, Savage PB,. Antimicrobial activities of amine- and guanidine-functionalized cholic acid derivatives. Antimicrob Agents Chemother 1999; 43: 1347-1349.
27. Savage PB,. Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria. Ann Med 2001; 33: 167-171.
28. Checketts RG, MacEachern AG, Otterburn M,. Pin track infection and the principles of pin site care. Berlin/Heidleberg/New York: Springer; 2000. pp 97-103.
29. Williams D, Bloebaum R, Petti CA,. Characterization of Staphylococcus aureus strains in a rabbit model of osseointegrated pin infections. J Biomed Mater Res A 2008; 85: 366-370.
30. Bloebaum RD, Bachus KN, Momberger NG, Hofmann AA,. Mineral apposition rates of human cancellous bone at the interface of porous coated implants. J Biomed Mater Res 1994; 28: 537-544.
31. Jansen JA, Dhert WJ, van der Waerden JP, von Recum AF,. Semi-quantitative and qualitative histologic analysis method for the evaluation of implant biocompatibility. J Invest Surg 1994; 7: 123-134.
32. Smeltzer MS, Thomas JR, Hickmon SG, Skinner RA, Nelson CL, Griffith D, Parr TR Jr, Evans RP,. Characterization of a rabbit model of staphylococcal osteomyelitis. J Orthop Res 1997; 15: 414-421.
33. Faber C, Hoogendoorn RJ, Stallmann HP, Lyaruu DM, van Nieuw Amerongen A, Wuisman PI,. In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model. J Antimicrob Chemother 2004; 54: 1078-1084.
34. Lucke M, Schmidmaier G, Sadoni S, Wildemann B, Schiller R, Haas NP, Raschke M,. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone 2003; 32: 521-531.
35. Steinstraesser L, Koehler T, Jacobsen F, Daigeler A, Goertz O, Langer S, Kesting M, Steinau H, Eriksson E, Hirsch T,. Host defense peptides in wound healing. Molecul Med 2008; 14: 528-537.
36. Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, Issbrucker K, Unterberger P, Zaiou M, Lebherz C, and others. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665-1672. Diseases